المؤلفون: Chowdhury, Subhankar, Ji, Linong, Suwanwalaikorn, Sompongse, Yu, Neng-Chun, Tan, Eng Kiat

المساهمون: Tan, EK (reprint author), Mt Elizabeth Med Ctr, Kevin Tan Clin Diabet Thyroid & Hormones, Singapore, Singapore., Inst Post Grad Med Educ & Res, Kolkata, India., Seth Sukhlal Karnani Mem Hosp, Kolkata, India., Peking Univ, Peoples Hosp, Beijing 100871, Peoples R China., Chulalongkorn Univ, Bangkok, Thailand., Yu Neng Chun Diabet Clin, Yi Lan, Taiwan., Kevin Tan Clin Diabet Thyroid & Hormones, Singapore, Singapore., Mt Elizabeth Med Ctr, Kevin Tan Clin Diabet Thyroid & Hormones, Singapore, Singapore.

المصدر: SCI

مصطلحات موضوعية: Diabetes education, Diabetes mellitus, Diabetes self-management, Glucometer, Insulin, Self-monitoring of blood glucose (SMBG), TYPE-2 DIABETES-MELLITUS, RANDOMIZED CONTROLLED-TRIAL, ALTERNATIVE MEDICINE USE, GLYCEMIC CONTROL, PRIMARY-CARE, METABOLIC-CONTROL, CARDIOVASCULAR-DISEASES, INTENSIVE TREATMENT, CLINICAL-PRACTICE, PHYSICAL-ACTIVITY

الوصف: Comprehensive glycemic control is necessary to improve outcomes and avoid complications in individuals with diabetes. Self-monitoring of blood glucose (SMBG) is a key enabler of glycemic assessment, providing real-time information that complements HbA1c monitoring and supports treatment optimization. However, SMBG is under-utilized by patients and physicians within the Asia-Pacific region, because of barriers such as the cost of monitoring supplies, lack of diabetes self-management skills, or concerns about the reliability of blood glucose readings. Practice recommendations in international and regional guidelines vary widely, and may not be detailed or specific enough to guide SMBG use effectively. This contributes to uncertainty among patients and physicians about how best to utilize this tool: when and how often to test, and what action(s) to take in response to high or low readings. In developing a practical SMBG regimen, the first step is to determine the recommended SMBG frequency and intensity needed to support the chosen treatment regimen. If there are practical obstacles to monitoring, such as affordability or access, physicians should identify the most important aspects of glycemic control to target for individual patients, and modify monitoring patterns accordingly. This consensus paper proposes a selection of structured, flexible SMBG patterns that can be tailored to the clinical, educational, behavioral, and financial requirements of individuals with diabetes. ; Medicine, General & Internal ; Medicine, Research & Experimental ; SCI(E) ; 0 ; ARTICLE ; dr@ktclinic.com ; 3 ; 461-476 ; 31

العلاقة: CURRENT MEDICAL RESEARCH AND OPINION.2015,31,(3),461-476.; 748080; http://hdl.handle.net/20.500.11897/206090Test; WOS:000351230800010

الإتاحة: https://doi.org/20.500.11897/206090Test
https://doi.org/10.1185/03007995.2015.1005832Test
https://hdl.handle.net/20.500.11897/206090Test

المؤلفون: Cai, Xiaoling, Han, Xueyao, Luo, Yingying, Ji, Linong

المساهمون: Ji, LN (reprint author), Peking Univ, Peoples Hosp, Dept Endocrinol & Metab, Beijing 100871, Peoples R China., Peking Univ, Peoples Hosp, Dept Endocrinol & Metab, Beijing 100871, Peoples R China.

المصدر: PubMed ; SCI

مصطلحات موضوعية: IMPROVES GLYCEMIC CONTROL, INTIMA-MEDIA THICKNESS, TREATED NIDDM PATIENTS, DOUBLE-BLIND, METABOLIC-CONTROL, ACARBOSE MONOTHERAPY, SULFONYLUREA THERAPY, COMBINATION THERAPY, INSULIN SENSITIVITY, 24-WEEK MONOTHERAPY

الوصف: Background: To compare the efficacy of glycemic control and insulin secretion of alpha glucosidase inhibitors (AGI) on type 2 diabetes patients between Asian and Caucasian. Methodology/Principal Findings: The MEDLINE (R), EMBASE (R), CENTRAL were searched and qualified studies in Asian and Caucasian population comparing AGI treatment with placebo or other oral anti-diabetic drugs in type 2 diabetic patients were included. Totally 58 qualified studies were included. When AGI treatment was compared with placebo, a significant difference in HbA1c decline from baseline favoring AGI treatment was found in Asian (weighted mean difference (WMD), -0.50%; 95% CI, -0.66% to -0.34%) and in Caucasian a significant difference in HbA1c decline favoring AGI treatment was also found (WMD, -0.68%; 95% CI, -0.76% to -0.60%). In Asian, fasting plasma glucose was reduced with AGI treatment compared with placebo (WMD, -0.53 mmol/L; 95% CI, -0.91 to -0.14 mmol/L) and in Caucasian there was also a significant difference in FPG changes favoring AGI therapy (WMD, -0.88 mmol/L; 95% CI, -1.00 to -0.77 mmol/L). Studies in Asian showed a significant difference in fasting insulin changes favoring AGI treatment (WMD, -0.78 uU/ml; 95% CI, -0.96 to -0.59 uU/ml). While in Caucasian fasting insulin was decreased without significance with AGI treatment (WMD-1.24 uU/ml; 95% CI, -2.51 to 0.04 uU/ml). Body weight was decreased with AGI treatment in Asian (WMD, -1.00 kg; 95% CI, -1.69 to -0.31 kg) and was also decreased with AGI treatment in Caucasian (WMD, -0.73 kg; 95% CI, -1.13 to -0.33 kg). Conclusions/Significance: According to results from this meta-analysis, the efficacy in glucose lowering, body weight reduction and insulin secretion decreasing of AGI treatment in Asian were comparable with those in Caucasian. ; Multidisciplinary Sciences ; SCI(E) ; PubMed ; 1 ; ARTICLE ; 11 ; e79421 ; 8

العلاقة: PLOS ONE.2013,8,(11).; 654560; http://hdl.handle.net/20.500.11897/159213Test; WOS:000327254700130

الإتاحة: https://doi.org/20.500.11897/159213Test
https://doi.org/10.1371/journal.pone.0079421Test
https://hdl.handle.net/20.500.11897/159213Test

المؤلفون: Pan, CY, Gao, Y, Chen, JW, Luo, BY, Fu, ZZ, Lu, JM, Guo, XH, Cheng, H

المساهمون: Pan, CY (reprint author), 28 Fu Xing Rd, Beijing, Peoples R China., Beijing Hosp 301, Beijing, Peoples R China., Peking Univ, Hosp 1, Beijing, Peoples R China., Jiang Su Province Hosp, Naijing, Peoples R China., Rui Jin Hosp, Shanghai, Peoples R China., Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China., 28 Fu Xing Rd, Beijing, Peoples R China.

المصدر: SCI

مصطلحات موضوعية: acarbose, Chinese/Asian population, impaired glucose tolerance, metabolic control, type 2 diabetes prevention, TYPE-2 DIABETES-MELLITUS, CARDIOVASCULAR-DISEASE, CLINICAL-IMPLICATIONS, DIAGNOSTIC-CRITERIA, FASTING GLUCOSE, LIFE-STYLE, NIDDM, PREVENTION, PREVALENCE, PLACEBO

الوصف: This multicentre, double-blind, placebo-controlled study investigated the efficacy of acarbose in Chinese individuals with impaired glucose tolerance (determined using a 75 g oral glucose tolerance test). Subjects were randomised to either placebo or acarbose 50 mg t.i.d. for a period of 16 weeks. Primary efficacy variables were the maximum postprandial plasma glucose value (C-max) and the serum insulin profile. Secondary efficacy parameters included postprandial glucose profile, maximum postprandial insulin concentration (C-max), changes in lipid profile and blood pressure and HbA(1c) and body weight and conversion to Type 2 diabetes. In the intention-to-treat analysis, acarbose treatment resulted in significantly higher reductions in postprandial glucose and serum insulin concentrations compared to placebo. Triglyceride concentration was the only lipid parameter to be significantly reduced in acarbose subjects. Loss of body weight was also significantly greater for acarbose than placebo subjects. Some 19 individuals converted to Type 2 diabetes (seven acarbose, 12 placebo), but this difference was not significant. Acarbose is efficacious in improving the metabolic state of individuals with impaired glucose tolerance indicating a potential benefit for the delay or prevention of onset of Type 2 diabetes in Chinese subjects. (C) 2003 Elsevier Ireland Ltd. All rights reserved. ; Endocrinology & Metabolism ; SCI(E) ; 22 ; ARTICLE ; 3 ; 183-190 ; 61

العلاقة: DIABETES RESEARCH AND CLINICAL PRACTICE.2003,61,(3),183-190.; 1011506; http://hdl.handle.net/20.500.11897/256122Test; WOS:000185503000006

الإتاحة: https://doi.org/20.500.11897/256122Test
https://doi.org/10.1016/S0168-8227Test(03)00117-7
https://hdl.handle.net/20.500.11897/256122Test